Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 (disitamab vedotin) + toripalimab in HER2-expressing high-risk NMIBC
ChiCTR2600128773Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in transitional cell carcinoma of the bladder (TCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Proportion of patients undergoing radical cystectomy at one year. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2600128773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128773.